Ginkgo Bioworks’ Acquisition of StrideBio’s Gene Therapy Assets

Foley Hoag represented Ginkgo Bioworks on the deal.Ginkgo Bioworks (NYSE: DNA) (“Ginkgo”), the leading platform for cell programming and biosecurity, announced its acquisition of StrideBio’s adeno-associated virus…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Martina Bellini

Author: Martina Bellini

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here